Valuation : Roche Holding AG

Market Cap 285B 352B 303B 261B 487B 33,261B 489B 3,370B 1,308B 17,065B 1,323B 1,294B 54,977B P/E 2026 *
19.9x
P/E 2027 * 17.6x
Enterprise Value 296B 366B 315B 270B 506B 34,529B 507B 3,499B 1,358B 17,716B 1,373B 1,343B 57,071B EV / Sales 2026 *
4.73x
EV / Sales 2027 * 4.42x
Free-Float
88.78%
Yield 2026 *
2.8%
Yield 2027 * 2.86%
Current month+0.48%
6 months-5.09%
Current year-1.29%
Current year 311.6
Extreme 311.6
377
1 year 252.3
Extreme 252.3
377
3 years 212.3
Extreme 212.3
377
5 years 212.3
Extreme 212.3
404.1
10 years 202.23
Extreme 202.231
404.1
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 352B
-0.88%-2.15%+58.05%+105.91% 1,024B
-1.15%+2.68%+54.25%+71.29% 663B
-1.44%+0.38%+20.65%+75.54% 453B
+0.14%-0.47%+30.20%+40.61% 352B
-1.33%+4.72%+24.62%+47.60% 304B
-1.15%+0.30%-0.69%+11.83% 252B
-1.55%+1.11%+54.15%+72.13% 236B
-0.88%+1.15%-14.60%-54.84% 206B
-0.15%+3.65%+31.24%+100.90% 187B
Average -0.84%+1.09%+28.65%+52.33% 408.71B
Weighted average by Cap. -0.88%+0.55%+37.63%+67.00%

Financials

2026 *2027 *
Net sales 62.61B 77.34B 66.55B 57.2B 107B 7,302B 107B 740B 287B 3,746B 290B 284B 12,069B 65.43B 80.82B 69.54B 59.77B 112B 7,630B 112B 773B 300B 3,915B 303B 297B 12,612B
Net income 14.5B 17.91B 15.41B 13.24B 24.77B 1,691B 24.84B 171B 66.47B 867B 67.24B 65.77B 2,794B 16.32B 20.15B 17.34B 14.91B 27.88B 1,903B 27.96B 193B 74.82B 976B 75.68B 74.03B 3,145B
Net Debt 10.87B 13.42B 11.55B 9.93B 18.57B 1,267B 18.62B 128B 49.83B 650B 50.4B 49.3B 2,095B 4.02B 4.96B 4.27B 3.67B 6.87B 469B 6.89B 47.5B 18.43B 241B 18.64B 18.24B 775B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
26-09-04 CHF 323.90 0.00% 7,764
26-09-03 CHF 323.90 0.00% 633
26-09-02 CHF 323.90 0.00% 202
26-09-01 CHF 323.90 0.00% 13,032
26-08-28 CHF 323.90 0.00% 173,926
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
357.00CHF
Average target price
370.31CHF
Spread / Average Target
+3.73%

Quarterly revenue - Rate of surprise